RIBS (Drug Discovery) Overview
- Year Founded
-
2025
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Seed
- Investors
-
1
RIBS (Drug Discovery) General Information
Description
Operator of a custom-made treatment company intended for aortic arch aneurysms. The company is currently operating in Stealth Mode.
Contact Information
Corporate Office
- 2-3-11 Nihonbashi Honcho
- Tokyo, 103-0023
- Japan
Corporate Office
- 2-3-11 Nihonbashi Honcho
- Tokyo, 103-0023
- Japan
RIBS (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 01-Jan-2026 | Completed | Stealth |
RIBS (Drug Discovery) Signals
RIBS (Drug Discovery) Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Diamond Medino Capital | Venture Capital | Minority |
RIBS (Drug Discovery) FAQs
-
When was RIBS (Drug Discovery) founded?
RIBS (Drug Discovery) was founded in 2025.
-
Where is RIBS (Drug Discovery) headquartered?
RIBS (Drug Discovery) is headquartered in Tokyo, Japan.
-
What is the size of RIBS (Drug Discovery)?
RIBS (Drug Discovery) has 10 total employees.
-
What industry is RIBS (Drug Discovery) in?
RIBS (Drug Discovery)’s primary industry is Drug Discovery.
-
Is RIBS (Drug Discovery) a private or public company?
RIBS (Drug Discovery) is a Private company.
-
What is RIBS (Drug Discovery)’s current revenue?
The current revenue for RIBS (Drug Discovery) is .
-
Who are RIBS (Drug Discovery)’s investors?
Diamond Medino Capital has invested in RIBS (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process